The American Association for the Study of Liver Disease (AASLD) states that MASLD affects over 30% of the global population and is now the primary cause of chronic liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major driver of hepatic disease and is associated with numerous conditions seen in primary care, such as prediabetes, type 2 diabetes, obesity, atherosclerosis, and dyslipidemia. Hepatic disease associated with MASLD exists on a spectrum and can progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Nomenclature of this condition, previously known as non-alcoholic fatty liver disease (NAFLD), has recently been revised.  This presentation will review the updated terminology, as well as review guidelines and recommendations that exist to help with screening, identification, monitoring, referral indications, and treatment of this disease.

Following the completion of this lecture, the participant will be able to:

1. Recognize updated terminology for liver steatosis
2. Identify patient populations being recommended for MASLD screening
3. Recall diagnostic criteria for MASLD
4. Understand how to utilize the FIB-4 risk score calculator to assess for advanced fibrosis in those with MASLD
5. Recall indications for second-line testing to evaluate liver fibrosis, such as transient elastography
6. Identify indications for referral to a liver specialist in patients with MASLD
7. Identify complications of MASLD and the spectrum of hepatic disease